Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss
Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss
The stock of Danish biotech Novo Nordisk was down 2.2% Tuesday, after a study found that the company’s obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.’s Mounjaro, in speed and magnitude of weight loss.
